Ultrasensitive Monitoring of HIV-1 Viral Load by a Low-Cost Real-Time Reverse Transcription-PCR Assay with Internal Control for the 5′ Long Terminal Repeat Domain

Abstract Background: Current HIV-1 viral-load assays are too expensive for resource-limited settings. In some countries, monitoring of antiretroviral therapy is now more expensive than treatment itself. In addition, some commercial assays have shown shortcomings in quantifying rare genotypes. Methods: We evaluated real-time reverse transcription-PCR with internal control targeting the conserved long terminal repeat (LTR) domain of HIV-1 on reference panels and patient samples from Brazil (n = 1186), South Africa (n = 130), India (n = 44), and Germany (n = 127). Results: The detection limit was 31.9 IU of HIV-1 RNA/mL of plasma (>95% probability of detection, Probit analysis). The internal control showed inhibition in 3.7% of samples (95% confidence interval, 2.32%–5.9%; n = 454; 40 different runs). Comparative qualitative testing yielded the following: Roche Amplicor vs LTR assay (n = 431 samples), 51.7% vs 65% positives; Amplicor Ultrasensitive vs LTR (n = 133), 81.2% vs 82.7%; BioMerieux NucliSens HIV-1 QT (n = 453), 60.5% vs 65.1%; Bayer Versant 3.0 (n = 433), 57.7% vs 55.4%; total (n = 1450), 59.0% vs 63.8% positives. Intra-/interassay variability at medium and near-negative concentrations was 18%–51%. The quantification range was 50–10 000 000 IU/mL. Viral loads for subtypes A–D, F–J, AE, and AG yielded mean differences of 0.31 log10 compared with Amplicor in the 103–104 IU/mL range. HIV-1 N and O were not detected by Amplicor, but yielded up to 180 180.00 IU/mL in the LTR assay. Viral loads in stored samples from all countries, compared with Amplicor, NucliSens, or Versant, yielded regression line slopes (SD) of 0.9 (0.13) (P <0.001 for all). Conclusions: This method offers all features of commercial assays and covers all relevant genotypes. It could allow general monitoring of antiretroviral therapy in resource-limited settings.

[1]  E. Schiff,et al.  Prospective Multicenter Clinical Evaluation of AMPLICOR and COBAS AMPLICOR Hepatitis C Virus Tests , 2001, Journal of Clinical Microbiology.

[2]  D. Hillyard,et al.  Use of lyophilized standards for the calibration of a newly developed real time PCR assay for human herpes type six (HHV6) variants A and B. , 2005, Journal of virological methods.

[3]  F. Nolte.  Novel internal controls for real-time PCR assays. , 2004, Clinical chemistry.

[4]  A. Heath,et al.  Establishment of the First International Standard for Nucleic Acid Amplification Technology (NAT) Assays for HCV RNA , 1999, Vox Sanguinis.

[5]  Christian Drosten,et al.  Rapid Detection and Quantification of RNA of Ebola and Marburg Viruses, Lassa Virus, Crimean-Congo Hemorrhagic Fever Virus, Rift Valley Fever Virus, Dengue Virus, and Yellow Fever Virus by Real-Time Reverse Transcription-PCR , 2002, Journal of Clinical Microbiology.

[6]  J. Fleisher,et al.  Underestimation of HIV-1 plasma viral burden in patients who acquire infection abroad: the experience in a community hospital clinic. , 2003, Archives of Internal Medicine.

[7]  J. Parry,et al.  Problems in the interpretation of HIV‐1 viral load assays using commercial reagents , 2000, Journal of medical virology.

[8]  L. Ivers,et al.  Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  J. Clarke.  Molecular diagnosis of HIV , 2002, Expert review of molecular diagnostics.

[10]  K. Stanecki,et al.  AIDS epidemic update December 2004. , 2004 .

[11]  H. Doerr,et al.  SARS Molecular Detection External Quality Assurance , 2004, Emerging infectious diseases.

[12]  M. Zazzi,et al.  Ultrasensitive in-house reverse transcription-competitive PCR for quantitation of HIV-1 RNA in plasma. , 2000, Journal of virological methods.

[13]  F. Bergmann,et al.  Comparison between a nucleic acid sequence-based amplification and branched DNA test for quantifying HIV RNA load in blood plasma. , 2000, Journal of virological methods.

[14]  R. Hodinka.  The clinical utility of viral quantitation using molecular methods. , 1998, Clinical and diagnostic virology.

[15]  K. Mayer,et al.  Low-cost monitoring of HIV infected individuals on highly active antiretroviral therapy (HAART) in developing countries. , 2005, The Indian journal of medical research.

[16]  Zehava Grosman,et al.  Measurement of HIV RNA in patients infected by subtype C by assays optimized for subtype B results in an underestimation of the viral load , 2004, Journal of medical virology.

[17]  D. Aubert,et al.  Multicenter Study of a Commercial, Automated Polymerase Chain Reaction System for the Rapid Detection of Mycobacterium tuberculosis in Respiratory Specimens in Routine Clinical Practice , 2001, European Journal of Clinical Microbiology and Infectious Diseases.

[18]  J. Parry,et al.  Accuracy of plasma HIV RNA quantification: A multicentre study of variability , 2000, Journal of medical virology.

[19]  A. Calmy,et al.  Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins Sans Frontières , 2003, AIDS.

[20]  D. Katzenstein,et al.  The evaluation of the HIV/AIDS Drug Access Initiatives in Côte D'Ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa , 2003, AIDS.

[21]  Jeffrey L. Jones,et al.  Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents , 2001, AIDS.

[22]  T. Kievits,et al.  NASBA: a novel, isothermal detection technology for qualitative and quantitative HIV-1 RNA measurements. , 1996, Clinics in laboratory medicine.

[23]  R. Dewar,et al.  Comparative Analysis of HIV‐1 Viral Load Assays on Subtype Quantification: Bayer Versant HIV‐1 RNA 3.0 Versus Roche Amplicor HIV‐1 Monitor Version 1.5 , 2002, Journal of acquired immune deficiency syndromes.

[24]  E. Dax,et al.  Advances in laboratory testing for HIV. , 2004, Pathology.

[25]  Allan J. Hance,et al.  HIV Drug Resistance , 2004 .

[26]  E. Seifried,et al.  TaqMan 5′-Nuclease Human Immunodeficiency Virus Type 1 PCR Assay with Phage-Packaged Competitive Internal Control for High-Throughput Blood Donor Screening , 2001, Journal of Clinical Microbiology.

[27]  F. Bastos,et al.  Human immunodeficiency virus/acquired immunodeficiency syndrome and tropical diseases: a Brazilian perspective. , 2000, Memorias do Instituto Oswaldo Cruz.

[28]  E. Stelzl,et al.  Evaluation of Automated Sample Preparation and Quantitative PCR LCx Assay for Determination of Human Immunodeficiency Virus Type 1 RNA , 2004, Journal of Clinical Microbiology.

[29]  E. Seifried,et al.  Evaluation of a new PCR assay with competitive internal control sequence for blood donor screening , 2000, Transfusion.

[30]  Establishment of the First International Standard for Nucleic Acid Amplification Technology (NAT) Assays for HCV RNA , 1999, Vox sanguinis.

[31]  H. Doerr,et al.  Quantification of Viral Load: Clinical Relevance for Human Immunodeficiency Virus, Hepatitis B Virus and Hepatitis C Virus Infection , 1998, Intervirology.

[32]  R. Valdiserri,et al.  Accomplishments in HIV prevention science: implications for stemming the epidemic , 2003, Nature Medicine.

[33]  H. Schatzmayr,et al.  Human immunodeficiency virus type 1: drug resistance in treated and untreated Brazilian children. , 2003, Memorias do Instituto Oswaldo Cruz.

[34]  C. Rowe.  Pneumocystis carinii pneumonia. , 1960, Radiology.

[35]  E. De Clercq,et al.  Failure to quantify viral load with two of the three commercial methods in a pregnant woman harboring an HIV type 1 subtype G strain. , 1998, AIDS research and human retroviruses.

[36]  Christian Drosten,et al.  First International Quality Assurance Study on the Rapid Detection of Viral Agents of Bioterrorism , 2004, Journal of Clinical Microbiology.

[37]  Peter J. Ell,et al.  December 2005 , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  A. Heath,et al.  An international collaborative study to establish the 1st international standard for HIV-1 RNA for use in nucleic acid-based techniques. , 2001, Journal of virological methods.

[39]  W. Hughes.  Pneumocystis carinii pneumonia , 2010 .

[40]  S. Günther,et al.  Evaluation of Advanced Reverse Transcription-PCR Assays and an Alternative PCR Target Region for Detection of Severe Acute Respiratory Syndrome-Associated Coronavirus , 2004, Journal of Clinical Microbiology.

[41]  A. Vandamme,et al.  Blinded, multicenter quality control study for the quantification of human immunodeficiency virus type 1 RNA in plasma by the Belgian AIDS reference laboratories. , 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[42]  K. Semrau,et al.  Quantitation of Human Immunodeficiency Virus Type 1 in Breast Milk , 2003, Journal of Clinical Microbiology.

[43]  F. Nolte,et al.  Branched DNA signal amplification for direct quantitation of nucleic acid sequences in clinical specimens. , 1998, Advances in clinical chemistry.

[44]  S. Khoo,et al.  Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection. , 2000, Therapeutic drug monitoring.

[45]  T. Jacob John.  HAART in India: heartening prospects & disheartening problems. , 2004, The Indian journal of medical research.

[46]  Maurice Rosenstraus,et al.  An Internal Control for Routine Diagnostic PCR: Design, Properties, and Effect on Clinical Performance , 1998, Journal of Clinical Microbiology.

[47]  Marly Marques da Cruz,et al.  Trends and characteristics of AIDS mortality in the Rio de Janeiro city after the introduction of highly active antiretroviral therapy. , 2005, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.